Clinica Chimica Acta:氨基末端b型利钠肽与b型利钠肽在住院心力衰竭患者预后中的应用

2019-08-06 Gladiator MedSci原创

本研究的目的是探讨氨基末端<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;; mso-fareast-font-family:宋体;mso-bidi-font-family:&quot;Times N

本研究的目的是探讨氨基末端b型利钠肽(NT-proBNP)b型利钠肽(BNP)联合应用对心力衰竭住院患者的预后是否具有额外的预测价值。

在本研究中,研究人员同时测量了1464名入院的心力衰竭患者的BNPNT-proBNP基线值。所有患者平均随访期间533 天。主要终点包括全因死亡(非移植患者)或心脏移植。

研究结果显示,NT-proBNP / BNP的中值摩尔比为2.37,但摩尔比的范围为1.573.75(较低的四分位数至较高的四分位数)。与低/低组(NT-proBNP <1790pg / mLBNP <495pg / mL),相比,对于NT-proBNP,使用1790pg / mL的临界值和来自ROC曲线分析的BNP495pg / mL,单变量Cox比例回归分析显示低/高组(NT-proBNP <1790pg / mLBNP≥495pg/ mL),高/低组(NT-proBNP≥1790pg/ mLBNP <495pg / mL)和高/高组(NT-proBNP≥1790pg/ mLBNP≥495pg/ mL )全因死亡或心脏移植的风险显着较高[HR(风险比):2.87,95CI(置信区间):1.69-4.89p <.001; HR2.68,95CI1.91-3.76p <.001; HR5.07,95CI3.85-6.67p <.001]。反过来,高/高组的全因死亡或心脏移植的风险高于低/高(HR1.70,95CI1.04-2.80p = .035)和高/低组(HR1.88 95CI1.42-2.49p <.001)。低/高和高/低组具有相似的全因死亡或心脏移植的风险。进一步的多变量Cox回归分析还显示BNPNT-proBNP均高于临界值,独立预测最差预后,而高于临界值的两种生物标志物中的任何一种都表明中度预后不良,均低于截止值表明是预后最好(趋势p <0.001)。

研究表明,心力衰竭患者血浆NT-proBNPBNP水平并不总是成比例增加。NT-proBNPBNP联合检测对预测住院心衰患者的不良事件有一定的预测价值。

原始出处:

YunhongWangRongchengZhangCombining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1777188, encodeId=60c71e7718897, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Mon Feb 10 00:00:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692065, encodeId=10a416920655f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Jun 15 14:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849653, encodeId=c0ed1849653e2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Feb 11 14:00:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366482, encodeId=cf43136648209, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Aug 08 04:00:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1777188, encodeId=60c71e7718897, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Mon Feb 10 00:00:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692065, encodeId=10a416920655f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Jun 15 14:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849653, encodeId=c0ed1849653e2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Feb 11 14:00:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366482, encodeId=cf43136648209, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Aug 08 04:00:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1777188, encodeId=60c71e7718897, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Mon Feb 10 00:00:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692065, encodeId=10a416920655f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Jun 15 14:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849653, encodeId=c0ed1849653e2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Feb 11 14:00:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366482, encodeId=cf43136648209, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Aug 08 04:00:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]
    2020-02-11 windight
  4. [GetPortalCommentsPageByObjectIdResponse(id=1777188, encodeId=60c71e7718897, content=<a href='/topic/show?id=824d381e70' target=_blank style='color:#2F92EE;'>#B型利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3817, encryptionId=824d381e70, topicName=B型利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=428c39117525, createdName=839640791, createdTime=Mon Feb 10 00:00:00 CST 2020, time=2020-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692065, encodeId=10a416920655f, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Jun 15 14:00:00 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849653, encodeId=c0ed1849653e2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Feb 11 14:00:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366482, encodeId=cf43136648209, content=<a href='/topic/show?id=76923233335' target=_blank style='color:#2F92EE;'>#利钠肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32333, encryptionId=76923233335, topicName=利钠肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Thu Aug 08 04:00:00 CST 2019, time=2019-08-08, status=1, ipAttribution=)]

相关资讯

老年人甲功异常高发,这几个关键检验指标必须记住

作为人体最大的内分泌腺,甲状腺在机体新陈代谢过程中发挥着重要作用。随着社会的老龄化,慢性疾病发病率逐年升高,多项研究提示,甲状腺功能异常与老年慢性疾病间存在着错综复杂的关系。

阴道炎经常找上门 老公该不该背“黑锅”

小梅33岁,从1年多之前开始,每隔两三个月,她就要得一次阴道炎,严重影响生活和工作。她第一次得的是念珠菌性阴道炎,白带呈豆腐渣样,外阴和阴道痒。用药后,很快就好了。

JCLA:五种对乙酰氨基酚检测方法的性能评价如何?

评价五种商品对乙酰氨基酚的分析性能,进而选择最佳的常规治疗方法。 研究人员在Beckman Coulter AU680化学分析仪上,对三种酶分析方法(Beckman Coulter AU Paracetamol, Abbott MULTIGENT Acetaminophen, Sekisui Acetaminophen L3K)和两种免疫分析方法(Beckman Coulter SYNCH

梅毒抗体阳性!宝宝感染梅毒?

“你们医院肯定弄错了,我娃这么小,怎么可能有梅毒!”一个年轻父亲站在检验科门口高声质问。“结果肯定错了,你们医院得给我一个说法!” 梅毒(syphilis)是由苍白(梅毒)螺旋体引起的慢性、系统性性传播疾病。主要通过性途径传播,临床上可表现为一期梅毒、二期梅毒、三期梅毒、潜伏梅毒和先天梅毒(胎传梅毒)等,是《中华人民共和国传染病防治法》中,列为乙类防治管理的病种。

药品走进便利店 发展如何还需时间检验

北京市印发《关于进一步促进便利店发展的若干措施》,其中明确提到“连锁便利店可按有关标准申请零售经营乙类非处方药”。针对此次药品进驻便利店的举措,作为一个为患者服务的药师,我站在药品消费者的立场进行一些探讨分析。

这次我们把白带常规讲清楚!

白带常规是一项全球一年要做数亿次的检查,光是报告单连起来都够绕地球好几圈了,可是能真正理解自己检查出来的结果的人又有多少呢?